Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 36.43 Billion KRW | -25.42% |
| 2022 | 48.85 Billion KRW | 91.78% |
| 2021 | 25.47 Billion KRW | 7.26% |
| 2020 | 23.74 Billion KRW | -1.16% |
| 2019 | 24.02 Billion KRW | 4.79% |
| 2018 | 22.92 Billion KRW | -6.93% |
| 2017 | 24.63 Billion KRW | 33.88% |
| 2016 | 18.4 Billion KRW | -62.2% |
| 2015 | 48.68 Billion KRW | -2.02% |
| 2014 | 49.68 Billion KRW | -0.45% |
| 2013 | 49.91 Billion KRW | -23.87% |
| 2012 | 65.56 Billion KRW | -19.54% |
| 2011 | 81.48 Billion KRW | -9.77% |
| 2010 | 90.31 Billion KRW | 62.3% |
| 2009 | 55.64 Billion KRW | 34.28% |
| 2008 | 41.43 Billion KRW | -55.94% |
| 2007 | 94.05 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 32.5 Billion KRW | -28.07% |
| 2024 Q1 | 45.18 Billion KRW | 24.01% |
| 2023 Q4 | 36.43 Billion KRW | 5.42% |
| 2023 Q1 | 71.7 Billion KRW | 46.78% |
| 2023 FY | 36.43 Billion KRW | -25.42% |
| 2023 Q3 | 34.56 Billion KRW | -2.77% |
| 2023 Q2 | 35.54 Billion KRW | -50.43% |
| 2022 Q2 | 46.16 Billion KRW | 64.82% |
| 2022 Q1 | 28.01 Billion KRW | 9.97% |
| 2022 FY | 48.85 Billion KRW | 91.78% |
| 2022 Q4 | 48.85 Billion KRW | -3.01% |
| 2022 Q3 | 50.37 Billion KRW | 9.1% |
| 2021 Q2 | 26.01 Billion KRW | -1.13% |
| 2021 FY | 25.47 Billion KRW | 7.26% |
| 2021 Q4 | 25.47 Billion KRW | 1.96% |
| 2021 Q1 | 26.3 Billion KRW | 10.78% |
| 2021 Q3 | 24.98 Billion KRW | -3.95% |
| 2020 Q2 | 24.96 Billion KRW | -4.51% |
| 2020 Q1 | 26.13 Billion KRW | 8.79% |
| 2020 Q3 | 22.61 Billion KRW | -9.39% |
| 2020 FY | 23.74 Billion KRW | -1.16% |
| 2020 Q4 | 23.74 Billion KRW | 5.0% |
| 2019 Q2 | 23.88 Billion KRW | -8.71% |
| 2019 Q4 | 24.02 Billion KRW | -6.0% |
| 2019 FY | 24.02 Billion KRW | 4.79% |
| 2019 Q1 | 26.15 Billion KRW | 14.09% |
| 2019 Q3 | 25.56 Billion KRW | 7.03% |
| 2018 FY | 22.92 Billion KRW | -6.93% |
| 2018 Q2 | 23.17 Billion KRW | -8.5% |
| 2018 Q4 | 22.92 Billion KRW | -0.41% |
| 2018 Q1 | 25.32 Billion KRW | 2.8% |
| 2018 Q3 | 23.02 Billion KRW | -0.64% |
| 2017 Q3 | 24.2 Billion KRW | 12.07% |
| 2017 Q1 | 23.21 Billion KRW | 26.15% |
| 2017 FY | 24.63 Billion KRW | 33.88% |
| 2017 Q4 | 24.63 Billion KRW | 1.76% |
| 2017 Q2 | 21.6 Billion KRW | -6.94% |
| 2016 Q3 | 20.19 Billion KRW | 2.87% |
| 2016 FY | 18.4 Billion KRW | -62.2% |
| 2016 Q4 | 18.4 Billion KRW | -8.87% |
| 2016 Q2 | 19.62 Billion KRW | -46.31% |
| 2016 Q1 | 36.55 Billion KRW | -24.91% |
| 2015 Q2 | 52.67 Billion KRW | 1.21% |
| 2015 Q3 | 47.83 Billion KRW | -9.17% |
| 2015 Q4 | 48.68 Billion KRW | 1.77% |
| 2015 FY | 48.68 Billion KRW | -2.02% |
| 2015 Q1 | 52.04 Billion KRW | 4.74% |
| 2014 Q3 | 59.2 Billion KRW | -2.85% |
| 2014 Q2 | 60.94 Billion KRW | 16.45% |
| 2014 FY | 49.68 Billion KRW | -0.45% |
| 2014 Q4 | 49.68 Billion KRW | -16.08% |
| 2014 Q1 | 52.33 Billion KRW | 4.84% |
| 2013 Q3 | 50.7 Billion KRW | 8.52% |
| 2013 Q4 | 49.91 Billion KRW | -1.56% |
| 2013 FY | 49.91 Billion KRW | -23.87% |
| 2013 Q1 | 69.57 Billion KRW | 6.12% |
| 2013 Q2 | 46.72 Billion KRW | -32.85% |
| 2012 Q4 | 65.56 Billion KRW | -3.09% |
| 2012 Q3 | 67.65 Billion KRW | -6.59% |
| 2012 Q2 | 72.43 Billion KRW | -22.82% |
| 2012 FY | 65.56 Billion KRW | -19.54% |
| 2012 Q1 | 93.85 Billion KRW | 15.18% |
| 2011 Q3 | 81.29 Billion KRW | -13.76% |
| 2011 Q1 | 89.88 Billion KRW | -0.47% |
| 2011 Q2 | 94.27 Billion KRW | 4.88% |
| 2011 FY | 81.48 Billion KRW | -9.77% |
| 2011 Q4 | 81.48 Billion KRW | 0.24% |
| 2010 Q2 | 56.1 Billion KRW | -2.88% |
| 2010 Q1 | 57.76 Billion KRW | 3.82% |
| 2010 Q4 | 90.31 Billion KRW | 39.32% |
| 2010 Q3 | 64.82 Billion KRW | 15.54% |
| 2010 FY | 90.31 Billion KRW | 62.3% |
| 2009 Q4 | 55.64 Billion KRW | 10.61% |
| 2009 Q3 | 50.3 Billion KRW | 22.81% |
| 2009 Q2 | 40.96 Billion KRW | -9.92% |
| 2009 Q1 | 45.47 Billion KRW | 9.74% |
| 2009 FY | 55.64 Billion KRW | 34.28% |
| 2008 Q1 | 104.7 Billion KRW | 11.33% |
| 2008 Q2 | 83.78 Billion KRW | -19.98% |
| 2008 FY | 41.43 Billion KRW | -55.94% |
| 2008 Q3 | 65.08 Billion KRW | -22.33% |
| 2008 Q4 | 41.43 Billion KRW | -36.33% |
| 2007 Q2 | 60.74 Billion KRW | 17.85% |
| 2007 Q3 | 90.15 Billion KRW | 48.4% |
| 2007 FY | 94.05 Billion KRW | 0.0% |
| 2007 Q4 | 94.05 Billion KRW | 4.33% |
| 2007 Q1 | 51.54 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 53.202% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 96.081% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 94.847% |
| HANDOK Inc. | 449.7 Billion KRW | 91.898% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 57.469% |
| Yuhan Corporation | 712.33 Billion KRW | 94.885% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 94.234% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -129.238% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 95.723% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | 31.931% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 82.302% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | 51.529% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 75.347% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | 48.245% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 53.202% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 85.492% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 83.491% |
| JW Holdings Corporation | 827.51 Billion KRW | 95.597% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 91.662% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 93.791% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 90.401% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 54.054% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | 47.924% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 84.997% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 88.969% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 53.202% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 92.564% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 95.753% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 90.401% |
| Yuhan Corporation | 712.33 Billion KRW | 94.885% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 92.374% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 73.398% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 92.948% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 90.401% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 76.422% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 59.5% |
| CKD Bio Corp. | 170.76 Billion KRW | 78.662% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 85.051% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 76.889% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | 15.302% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 54.054% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 94.24% |
| Boryung Corporation | 373.1 Billion KRW | 90.234% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 82.499% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 82.302% |
| JW Lifescience Corporation | 96.44 Billion KRW | 62.22% |